Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.79 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | LTA4H | P09960 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4261838 | 0.83 | EPHX2 (1.00) | EPHX2MAPTALDH1A1HTTRAB9A | |
| SCHEMBL4974321 | 0.82 | EPHX2 (0.70) | EPHX2ALDH1A1LTA4HRAB9A | |
| SCHEMBL10378 | 0.81 | LIPE (0.58) | EPHX2MAPTALDH1A1LMNARAB9A | |
| SCHEMBL31427171 | 0.81 | LTA4H (0.64) | EPHX2ALDH1A1LMNALTA4HRAB9A | |
| SCHEMBL9505612 | 0.80 | THRB (0.63) | EPHX2MAPTALDH1A1LMNA | |
| SCHEMBL10132797 | 0.80 | EPHX2 (0.67) | EPHX2MAPTALDH1A1LMNALTA4H | |
| SCHEMBL10132861 | 0.80 | NPC1 (0.63) | EPHX2ALDH1A1LTA4HRAB9A | |
| SCHEMBL11926736 | 0.79 | KDM4E (0.65) | EPHX2ALDH1A1 | |
| SCHEMBL22500248 | 0.79 | MAPT (1.00) | EPHX2MAPTALDH1A1LMNACYP2C19 | |
| SCHEMBL4256144 | 0.78 | EPHX2 (1.00) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558567-B1 | NOVEL AMIDE COMPOUNDS WITH MCH ANTAGONISTIC EFFECT AND MEDICAMENTS COMPRISING SAID COMPOUNDS | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-06-24 | — | — | EP | claimed |
| JP-2006504761-A | — | — | 2006-02-09 | — | — | JP | claimed |
| EP-1558567-A1 | NOVEL AMIDE COMPOUNDS WITH MCH ANTAGONISTIC EFFECT AND MEDICAMENTS COMPRISING SAID COMPOUNDS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-03 | — | — | EP | claimed |
| US-20040152742-A1 | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-08-05 | — | — | US | claimed |
| WO-2004039764-A1 | NOVEL AMIDE COMPOUNDS WITH MCH ANTAGONISTIC EFFECT AND MEDICAMENTS COMPRISING SAID COMPOUNDS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-13 | — | — | WO | claimed |
| EP-1558567-B1 | NOVEL AMIDE COMPOUNDS WITH MCH ANTAGONISTIC EFFECT AND MEDICAMENTS COMPRISING SAID COMPOUNDS | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-06-24 | — | — | EP | disclosed |
| US-7351719-B2 | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-04-01 | — | — | US | disclosed |
| EP-1558567-A1 | NOVEL AMIDE COMPOUNDS WITH MCH ANTAGONISTIC EFFECT AND MEDICAMENTS COMPRISING SAID COMPOUNDS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-03 | — | — | EP | disclosed |
| US-20040152742-A1 | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-08-05 | — | — | US | disclosed |
| WO-2004039764-A1 | NOVEL AMIDE COMPOUNDS WITH MCH ANTAGONISTIC EFFECT AND MEDICAMENTS COMPRISING SAID COMPOUNDS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152742-A1 | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds | MCHR2, MCHR1, NPY1R | EPHX2 1478/4885MAPT 4346/4885ALDH1A1 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.